English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.
Tag: Nash
Phase II Trial Studies Effects of Semaglutide Medication in Patients with NASH
Nonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis…
Lactating Mice Pass along Common Antimicrobial to Pups, Initiating Liver Damage
In mouse studies, UC San Diego researchers report that lactating mothers expose their feeding pups to triclosan, an antimicrobial commonly used in consumer products, resulting in early signs of liver damage.
New Potential Therapy for Fatty Liver Disease
In a subset of patients with partial lipodystrophy and/or NASH, the hormone leptin can be leveraged as a therapeutic agent to move fat out of the liver.
Diet Plays Critical Role in NASH Progressing to Liver Cancer in Mouse Model
Researchers at University of California San Diego School of Medicine found in a mouse model that when fed a Western diet rich in calories, fat and cholesterol, the mice progressively became obese, diabetic and developed NASH, which progressed to HCC, chronic kidney and cardiovascular disease.
Sulfatase 2 Plays Role in Development of Obesity-induced Fatty Liver Disease
Article title: Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease Authors: Tae Hyo Kim, Bubu A. Banini,* Faizal Z. Asumda, Nellie A. Campbell, Chunling Hu, Catherine D. Moser, Abdirashid…
Three non-invasive methods used to predict who has NASH agree only about 20% of the time
Researchers and clinicians have been trying to find a way to diagnose nonalcoholic steatohepatitis (NASH) without taking a liver tissue biopsy, but according to new research, formulas that aim to predict NASH based on risk factors do not agree with each other and their accuracy varies. The study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Study: Two Enzymes Control Liver Damage in NASH
After identifying a molecular pathway that allows nonalcoholic steatohepatitis (NASH) to progress into liver cell death, University of California San Diego School of Medicine researchers were able to use these pathways to halt further liver damage.
Liver Fibrosis “Off Switch” Discovered in Mice
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen — providing a new therapeutic target for liver fibrosis.
New Drug Prevents Liver Damage, Obesity and Glucose Intolerance in Mice on High-Fat Diet
Mice given a new drug targeting a key gene involved in lipid and glucose metabolism could tolerate a high-fat diet regimen (composed of 60% fat from lard) without developing significant liver damage, becoming obese, or disrupting their body’s glucose balance.